Connectivity between mitochondrial functions and psychiatric disorders

Psychiatry and Clinical Neurosciences

Volumn 65, Issue 2, 2011, Pages 130-141

  Hroudová, Jana ^a,b   Fišar, Zdeněk ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

antidepressants; mitochondria; mitochondrial DNA; mood disorders; mood stabilizers

Indexed keywords

ADENOSINE TRIPHOSPHATE; AMITRIPTYLINE; ARIPIPRAZOLE; CALCIUM; CARBAMAZEPINE; CHLORPROMAZINE; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; FLUOXETINE; FLUPHENAZINE; FREE RADICAL; HALOPERIDOL; IMIPRAMINE; LAMOTRIGINE; LITHIUM; MIRTAZAPINE; MITOCHONDRIAL DNA; MITOCHONDRIAL RNA; NORTRIPTYLINE; OLANZAPINE; PAROXETINE; QUETIAPINE; REACTIVE OXYGEN METABOLITE; TRANYLCYPROMINE; VALPROIC ACID;

ANXIETY DISORDER; APOPTOSIS; BIPOLAR DISORDER; BORDERLINE STATE; CELL FUNCTION; CELL STRUCTURE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA DAMAGE; DNA FRAGMENTATION; DNA POLYMORPHISM; ECHO PLANAR IMAGING; ENERGY YIELD; GENE DELETION; HUMAN; MAJOR DEPRESSION; MENTAL DISEASE; MOOD DISORDER; MUTATION; NERVE CELL PLASTICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OXIDATION REDUCTION REACTION; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; POSITRON EMISSION TOMOGRAPHY; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 79952918437     PISSN: 13231316     EISSN: 14401819     Source Type: Journal    
DOI: 10.1111/j.1440-1819.2010.02178.x     Document Type: Review

References (126)

1. Vélot C, Srere PA,. Reversible transdominant inhibition of a metabolic pathway. In vivo evidence of interaction between two sequential tricarboxylic acid cycle enzymes in yeast. J. Biol. Chem. 2000; 275: 12926-12933. (Pubitemid 30241449)
2. Sriram G, Martinez JA, McCabe ER, Liao JC, Dipple KM,. Single-gene disorders: what role could moonlighting enzymes play? Am. J. Hum. Genet. 2005; 76: 911-924. (Pubitemid 40705429)
3. Mitchell P,. Coupling of phosphorylation to electron and hydrogen transfer by a chemi-osmotic type of mechanism. Nature 1961; 191: 144-148.
4. Davey GP, Peuchen S, Clark JB,. Energy thresholds in brain mitochondria: potential involvement in neurodegeneration. J. Biol. Chem. 1998; 273: 12753-12757. (Pubitemid 28246828)
5. Ben-Shachar D, Karry R,. Neuroanatomical pattern of mitochondrial complex I pathology varies between schizophrenia, bipolar disorder and major depression. PLoS ONE 2008; 3: e3676.
6. Scheffler IE,. Molecular genetics of succinate: quinone oxidoreductase in eukaryotes. Prog. Nucleic Acid Res. Mol. Biol. 1998; 60: 267-315.
7. Müller U, Troidl C, Niemann S,. SDHC mutations in hereditary paraganglioma/pheochromocytoma. Fam. Cancer 2005; 4: 9-12. (Pubitemid 40754839)
8. Holt IJ, Harding AE, Morgan-Hughes JA,. Deletions of muscle mitochondrial DNA in patients with mitochondrial myopathies. Nature 1988; 331: 717-719. (Pubitemid 18062238)
9. Wallace DC, Singh G, Lott MT, et al,. Mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy. Science 1988; 242: 1427-1430. (Pubitemid 19008070)
10. Shoffner JM, Lott MT, Lezza AM, Seibel P, Ballinger SW, Wallace DC,. Myoclonic epilepsy and ragged-red fiber disease (MERRF) is associated with a mitochondrial DNA tRNA(Lys) mutation. Cell 1990; 61: 931-937.
11. Wallace DC,. A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine. Annu. Rev. Genet. 2005; 39: 359-407. (Pubitemid 43011120)
12. Kirk R, Furlong RA, Amos W, et al,. Mitochondrial genetic analyses suggest selection against maternal lineages in bipolar affective disorder. Am. J. Hum. Genet. 1999; 65: 508-518. (Pubitemid 30463008)
13. Wallace DC, Shoffner JM, Trounce I, et al,. Mitochondrial DNA mutations in human degenerative diseases and aging. Biochim. Biophys. Acta 1995; 127: 141-151.
14. Cadenas E, Davies KJ,. Mitochondrial free radical generation, oxidative stress, and aging. Free Radic. Biol. Med. 2000; 29: 222-230.
15. Halliwell B,. Oxidative stress and neurodegeneration: where are we now? J. Neurochem. 2006; 97: 1634-1658. (Pubitemid 43873658)
16. Afonso V, Champy R, Mitrovic D, Collin P, Lomri A,. Reactive oxygen species and superoxide dismutases: role in joint diseases. Joint Bone Spine 2007; 74: 324-329. (Pubitemid 47049827)
17. Mahadik SP, Mukherjee S,. Free radical pathology and antioxidant defense in schizophrenia: a review. Schizophr. Res. 1996; 19: 1-17. (Pubitemid 26133208)
18. Ranjekar PK, Hinge A, Hegde MV, et al,. Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients. Psychiatry Res. 2003; 121: 109-122. (Pubitemid 37500981)
19. Naoi M, Maruyama W, Akao Y, Yi H, Yamaoka Y,. Involvement of type A monoamine oxidase in neurodegeneration: regulation of mitochondrial signaling leading to cell death or neuroprotection. J. Neural Transm. Suppl. 2006; 71: 67-77. (Pubitemid 351412108)
20. Coyle JT, Puttfarcken P,. Oxidative stress, glutamate, and neurodegenerative disorders. Science 1993; 262: 689-695. (Pubitemid 23350687)
21. White BC, Aust SD, Arforts KE, Aronson LD,. Brain injury by ischemic anoxia: hypothesis extension-a tale of two ions? Ann. Emerg. Med. 1984; 13: 862-867. (Pubitemid 14029853)
22. Gilgun-Sherki Y, Rosenbaum Z, Melamed E, Offen D,. Antioxidant therapy in acute central nervous system injury: current state. Pharmacol. Rev. 2002; 54: 271-284. (Pubitemid 34575717)
23. McCormack JG, Halestrap AP, Denton RM,. Role of calcium ions in regulation of mammalian intramitochondrial metabolism. Physiol. Rev. 1990; 70: 391-425. (Pubitemid 20140186)
24. Rizzuto R, Bernardi P, Pozzan T,. Mitochondria as all-round players of the calcium game. J. Physiol. 2000; 529: 37-47.
25. Starkov AA, Fiskum G, Chinopoulos C, et al,. Mitochondrial alpha-ketoglutarate dehydrogenase complex generates reactive oxygen species. J. Neurosci. 2004; 24: 7779-7788. (Pubitemid 39215681)
26. Nicholls DG,. Mitochondrial calcium function and dysfunction in the central nervous system. Biochim. Biophys. Acta 2009; 1787: 1416-1424.
27. Kirkland RA, Franclin JL,. Bax, reactive oxygen, and cytochrome c release in neuronal apoptosis. Antioxid. Redox Signal. 2003; 5: 589-596. (Pubitemid 37315147)
28. Kosten TA, Galloway MP, Duman RS, Russell DS, D'Sa C,. Repeated unpredictable stress and antidepressants differentially regulate expression of the bcl-2 family of apoptotic genes in rat cortical, hippocampal, and limbic brain structures. Neuropsychopharmacology 2008; 33: 1545-1558. (Pubitemid 351684697)
29. Mattson MP, Gleichmann M, Cheng A,. Mitochondria in neuroplasticity and neurological disorders. Neuron 2008; 60: 748-766.
30. Bredesen DE, Rao RV, Mehlen P,. Cell death in the nervous system. Nature 2006; 443: 796-802. (Pubitemid 44622684)
31. Brunelle JK, Letai A,. Control of mitochondrial apoptosis by the Bcl-2. J. Cell Sci. 2009; 122: 437-441.
32. Cory S, Adams JM,. The Bcl-2 family: regulators of the cellular life-or-death switch. Nat. Rev. Cancer 2002; 2: 647-656. (Pubitemid 37328916)
33. Bolaños JP, Moro MA, Lizasoain I, Almeida A,. Mitochondria and reactive oxygen and nitrogen species in neurological disorders and stroke: therapeutic implications. Adv. Drug Deliv. Rev. 2009; 61: 1299-1315.
34. 2+ as a key regulator of cell life and death. Cell Death Differ. 2007; 14: 1267-1274. (Pubitemid 46965258)
35. Mattson MP, Partin J,. Evidence for mitochondrial control of neuronal polarity. J. Neurosci. Res. 1999; 56: 8-20. (Pubitemid 29190611)
36. Erecinska M, Cherian S, Silver IA,. Energy metabolism in mammalian brain during development. Prog. Neurobiol. 2004; 73: 397-445. (Pubitemid 39099270)
37. Chada SR, Hollenberck PJ,. Nerve growth factor signaling regulates motility and docking of axonal mitochondria. Curr. Biol. 2004; 14: 1272-1276. (Pubitemid 38991815)
38. Chang DT, Reynolds IJ,. Differences in mitochondrial movement and morphology in young and mature primary cortical neurons in culture. Neuroscience 2006; 141: 727-736. (Pubitemid 44066636)
39. Fišar Z, Hroudová J,. Common aspects of neuroplasticity, mood disorders and mitochondrial functions. Act. Nerv. Super. Rediviva. 2010; 52: 3-20.
40. Cai Q, Sheng ZH,. Mitochondrial transport and docking in axons. Exp. Neurol. 2009; 218: 257-267.
41. Stamer K, Vogel R, Thies E, Mandelkow E, Mandelkow EM,. Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress. J. Cell Biol. 2002; 156: 1051-1063. (Pubitemid 34839854)
42. Overly CC, Rieff HI, Hollenberck PJ,. Organelle motility and metabolism in axons vs dendrites of cultured hippocampal neurons. J. Cell Sci. 1996; 109: 971-980. (Pubitemid 26168250)
43. Cocco T, Pacelli C, Sgobbo P, Villani G,. Control of OXPHOS efficiency by complex I in brain mitochondria. Neurobiol. Aging. 2009; 30: 622-629.
44. Markham A, Cameron I, Franklin P, Spedding M,. BDNF increases rat brain mitochondrial respiratory coupling at complex I, but not complex II. Eur. J. Neurosci. 2004; 20: 1189-1196. (Pubitemid 39233572)
45. Ruthel G, Hollenberck PJ,. Response of mitochondrial traffic to axon determination and differential branch growth. J. Neurosci. 2003; 23: 8618-8624. (Pubitemid 37158761)
46. Shao L, Martin MV, Watson SJ, et al,. Mitochondrial involvement in psychiatric disorders. Ann. Med. 2008; 40: 281-295. (Pubitemid 351563935)
47. Jou SH, Chiu NY, Liu CS,. Mitochondrial dysfunction and psychiatric disorders. Chang Gung Med. J. 2009; 32: 370-379.
48. Fattal O, Budur K, Vaughan AJ, Franco K,. Review of the literature on major mental disorders in adult patients with mitochondrial diseases. Psychosomatics 2006; 47: 1-7. (Pubitemid 43017115)
49. Rollins B, Martin MV, Sequeira PA, et al,. Mitochondrial variants in schizophrenia, bipolar disorder, and major depressive disorder. PloS ONE 2009; 4: e4913.
50. Washizuka S, Kametani M, Sasaki T, et al,. Association of mitochondrial complex I subunit gene NDUFV2 at 18p11 with schizophrenia in the Japanese population. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2006; 141: 301-304.
51. Kato T, Kunugi H, Nanko S, Kato N,. Mitochondrial DNA polymorphisms in bipolar disorder. J. Affect. Disord. 2001; 62: 151-164. (Pubitemid 32167082)
52. Clay H, Sillivan S, Konradi C,. Mitochondrial dysfunction and pathology in bipolar disorder and schizophrenia. Int. J. Dev. Neurosci. 2010; DOI:10.1016/j.ijdevneu.2010.08.007.
53. Iwamoto K, Bundo M, Kato T,. Altered expression of mitochondria-related genes in postmortem brains of patients with bipolar disorder or schizophrenia, as revealed by large-scale DNA microarray analysis. Hum. Mol. Genet. 2005; 14: 241-253.
54. Kato T, Kato N,. Mitochondrial dysfunction in bipolar disorder. Bipolar Disord. 2000; 2: 180-190.
55. Kato T,. Role of mitochondrial DNA in calcium signaling abnormality in bipolar disorder. Cell Calcium. 2008; 44: 92-102.
56. Stork C, Renshaw RF,. Mitochondrial dysfunction in bipolar disorder: evidence from magnetic resonance spectroscopy research. Mol. Psychiatry 2005; 10: 900-919. (Pubitemid 41486483)
57. Frey BN, Andreazza AC, Nery FG, et al,. The role of hippocampus in the pathophysiology of bipolar disorder. Behav. Pharmacol. 2007; 18: 419-430. (Pubitemid 47356368)
58. 1H MRS study. Bipolar Disord. 2007; 9: 119-127. (Pubitemid 47399254)
59. 31P-magnetic resonance spectroscopic findings to their molecular mechanisms. Int. Rev. Neurobiol. 2005; 63: 21-40. (Pubitemid 43588574)
60. Dager SR, Friedman SD, Parow A, et al,. Brain metabolic alterations in medication-free patients with bipolar disorder. Arch. Gen. Psychiatry 2004; 61: 450-458. (Pubitemid 38620843)
61. Rajkowska G,. Cell pathology in bipolar disorder. Bipolar Disord. 2002; 4: 105-116. (Pubitemid 34411273)
62. Strakowski SM, Delbello MP, Adler CM,. The functional neuroanatomy of bipolar disorder: a review of neuroimaging findings. Mol. Psychiatry 2005; 10: 105-116. (Pubitemid 40139591)
63. Vawter MP, Tomita H, Meng F, et al,. Mitochondrial-related gene expression changes are sensitive to agonal-pH state: implications for brain disorders. Mol. Psychiatry 2006; 11: 663-679. (Pubitemid 43989813)
64. Zipursky RB, Meyer JH, Verhoeff NP,. PET and SPECT imaging in psychiatric disorders. Can. J. Psychiatry 2007; 52: 146-157. (Pubitemid 46761957)
65. Videbech P,. PET measurements of brain glucose metabolism and blood flow in major depressive disorder: a critical review. Acta Psychiatr. Scand. 2000; 101: 11-20. (Pubitemid 30041119)
66. Buchsbaum MS, Hazlett EA,. Positron emission tomography studies of abnormal glucose metabolism in schizophrenia. Schizophr. Bull. 1998; 24: 343-346.
67. Gur RE, Resnick SM, Gur RC, et al,. Regional brain function in schizophrenia. II. Repeated evaluation with positron emission tomography. Arch. Gen. Psychiatry 1987; 44: 126-129. (Pubitemid 17006451)
68. Tamminga CA, Thaker GK, Buchanan R, et al,. Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome. Arch. Gen. Psychiatry 1992; 49: 522-530.
69. Holcomb HH, Cascella NG, Thaker GK, Medoff DR, Dannals RF, Tamminga CA,. Functional sites of neuroleptic drug action in the human brain: PET/FDG studies with and without haloperidol. Am. J. Psychiatry 1996; 153: 41-49. (Pubitemid 26026156)
70. 31P magnetic resonance chemical shift imaging. Acta Psychiatr. Scand. 1992; 86: 455-462.
71. 31P nuclear magnetic resonance spectroscopy: neurodevelopment and schizophrenia. Schizophr. Bull. 1993; 19: 35-53. (Pubitemid 23073554)
72. 31P-spectroscopy of frontal lobe in schizophrenia: alterations in phospholipid and high-energy phosphate metabolism. Schizophr. Res. 2002; 58: 117-122. (Pubitemid 35284503)
73. Fukuzako H, Fukuzako T, Hashiguchi T, Kodama S, Takigawa M, Fujimoto T,. Changes in levels of phosphorus metabolites in temporal lobes of drug-naîve schizophrenic patients. Am. J. Psychiatry 1999; 88: 1205-1208. (Pubitemid 29374880)
74. Reddy R, Keshavan MS,. Phosphorus magnetic resonance spectroscopy: its utility in examining the membrane hypothesis of schizophrenia. Prostaglandins Leukot. Essent. Fatty Acids. 2003; 69: 401-405. (Pubitemid 37464049)
75. Deicken RF, Johnson C, Pegues M,. Proton magnetic resonance spectroscopy of the human brain in schizophrenia. Rev. Neurosci. 2000; 11: 147-158. (Pubitemid 30133166)
76. Harrison PJ, Weinberger DR,. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol. Psychiatry 2005; 10: 40-68. (Pubitemid 40139588)
77. Da Prada M, Cesura AM, Launay JM, Richards JG,. Platelets as a model for neurones? Experientia 1988; 44: 115-126. (Pubitemid 18074244)
78. Camacho A, Dimsdale JE,. Platelets in psychiatry: lessons learned from old to new studies. Psychosom. Med. 2000; 62: 326-336. (Pubitemid 30347076)
79. Ben-Shachar D,. The interplay between mitochondrial complex I, dopamine and Sp1 in schizophrenia. J. Neural Transm. 2009; 116: 1383-1396.
80. Martorell L, Segués T, Folch G, et al,. New variants in the mitochondrial genomes of schizophrenic patients. Eur. J. Hum. Genet. 2006; 14: 520-528.
81. McMahon FJ, Chen YS, Patel S, et al,. Mitochondrial DNA sequence diversity in bipolar affective disorder. Am. J. Psychiatry 2000; 157: 1058-1064. (Pubitemid 30432484)
82. Wong-Riley MT,. Cytochrome oxidase: an endogenous metabolic marker for neuronal activity. Trends Neurosci. 1989; 12: 94-101. (Pubitemid 19067056)
83. Prince JA, Blennow K, Gittfries CG, Karlsson I, Oreland L,. Mitochondria function is differentially altered in the basal ganglia of chronic schizophrenics. Neuropharmacology 1999; 21: 372-379. (Pubitemid 29333075)
84. Maurer I, Zierz S, Möller H,. Evidence for a mitochondrial oxidative phosphorylation defect in brains from patients with schizophrenia. Schizophr. Res. 2001; 38: 125-136. (Pubitemid 32241188)
85. Cavelier L, Jazin EE, Eriksson I, et al,. Decreased cytochrome-c oxidase activity and lack of age-related accumulation of mitochondrial DNA deletions in the brain of schizophrenics. Genomics 1995; 29: 217-224.
86. Prince JA, Harro J, Blennow K, Gottfries CG, Oreland L,. Putamen mitochondrial energy metabolism is highly correlated to emotional and intellectual impairment in schizophrenics. Neuropsychopharmacology 2000; 22: 284-292. (Pubitemid 30089539)
87. Duman RS,. Depression: a case of neuronal life and death? Biol. Psychiatry 2004; 56: 140-145. (Pubitemid 38969145)
88. Fišar Z,. Inhibition of monoamine oxidase activity by cannabinoids. Naunyn Schmiedebergs Arch. Pharmacol. 2010; 381: 563-572.
89. Fišar Z, Hroudová J, Raboch J,. Inhibition of monoamine oxidase activity by antidepressants and mood stabilizers. Neuro. Endocrinol. Lett. 2010; 31: 101-112.
90. Hroudova J, Fisar Z,. Activities of respiratory chain complexes and citrate synthase influenced by pharmacologically different antidepressants and mood stabilizers. Neuro. Endocrinol. Lett. 2010; 31: 336-342.
91. Weinbach EC, Costa JL, Nelson BD, et al,. Effects of tricyclic antidepressant drugs on energy-linked reactions in mitochondria. Biochem. Pharmacol. 1986; 35: 1445-1451. (Pubitemid 16037997)
92. Katyare SS, Rajan RR,. Effect of long-term in vivo treatment with imipramine on the oxidative energy metabolism in rat brain mitochondria. Comp. Biochem. Psysiol. C. Pharmacol. Toxicol. Endocrinol. 1995; 112: 353-357. (Pubitemid 26038873)
93. Dykens JA, Jamieson JD, Marroquin LD, et al,. In vitro assessment of mitochondrial dysfunction and cytotoxicity of nefazodone, trazodone, and buspirone. Toxicol. Sci. 2008; 103: 335-345. (Pubitemid 351659605)
94. Velasco A, González-Calvo V, Alvarez FJ, Dueñas A, García-Roldán JL,. Effect of trazodone on oxidative metabolism of rat brain in vitro. Rev. Esp. Fisiol. 1985; 41: 201-205.
95. L. Biochem. Pharmacol. 1999; 57: 1199-1208. (Pubitemid 29171696)
96. Levkovitz Y, Gil-Ad I, Zeldich E, Dayag M, Weizman A,. Differential induction of apoptosis by antidepressants in glioma and neuroblastoma cell lines: evidence for p-c-Jun, cytochrome c, and caspase-3 involvement. J. Mol. Neurosci. 2005; 27: 29-42. (Pubitemid 41112377)
97. Ma J, Qiu Y, Yang L, et al,. Desipramine induces apoptosis in rat glioma cells via endoplasmic reticulum stress-dependent CHOP pathway. J. Neurooncol. 2010; 101: 41-48.
98. Kolla N, Wei Z, Richardson JS, Li XM,. Amitriptyline and fluoxetine protect PC12 cells from cell death induced by hydrogen peroxide. J. Psychiatry Neurosci. 2005; 30: 196-201. (Pubitemid 40942458)
99. Han YS, Lee CS,. Antidepressants reveal differential effect against 1-methyl-4-phenylpyridinium toxicity in differentiated PC12 cells. Eur. J. Pharmacol. 2009; 604: 36-44.
100. Wang H, Guan Y, Wang X, et al,. Nortriptyline delays disease onset in models of chronic neurodegeneration. Eur. J. Neurosci. 2007; 26: 633-641. (Pubitemid 47206781)
101. Zhang WH, Wang H, Wang X, et al,. Nortriptyline protects mitochondria and reduces cerebral ischemia/hypoxia injury. Stroke 2008; 38: 455-462. (Pubitemid 351619471)
102. Chen G, Zeng WZ, Yuan PX, et al,. The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. J. Neurochem. 1999; 72: 879-882. (Pubitemid 29055256)
103. Gould TD, Manji HK,. Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs. Neuropsychopharmacology 2005; 30: 1223-1237. (Pubitemid 40848077)
104. Maurer IC, Schippel P, Volz HP,. Lithium-induced enhancement of mitochondrial oxidative phosphorylation in human brain tissue. Bipolar Disord. 2009; 11: 515-522.
105. Nonaka S, Hough CJ, Chuang DM,. Chronic lithium treatment robustly protects neurons in the central nervous system against excitotoxicity by inhibiting N-methyl-D-aspartate receptor-mediated calcium influx. Proc. Natl. Acad. Sci. U.S.A. 1998; 95: 2642-1647.
106. Shalbuyeva N, Brustovetsky T, Brustovetsky N,. Lithium desensitizes brain mitochondria to calcium, antagonizes permeability transition, and diminishes cytochrome C release. J. Biol. Chem. 2007; 282: 18057-18068. (Pubitemid 47100223)
107. Haas R, Stumpf DA, Parks JK, Eguren L,. Inhibitory effects of sodium valproate on oxidative phosphorylation. Neurology 1981; 31: 1473-1476. (Pubitemid 12228288)
108. Corrêa C, Amboni G, Assis LC, et al,. Effects of lithium and valproate on hippocampus citrate synthase activity in an animal model of mania. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007; 31: 887-891. (Pubitemid 46660301)
109. Lai JS, Zhao C, Warsh JJ, Li PP,. Cytoprotection by lithium and valproate varies between cell types and cellular stresses. Eur. J. Pharmacol. 2006; 539: 18-26. (Pubitemid 43783516)
110. Bachmann RF, Wang Y, Yuan P, et al,. Common effects of lithium and valproate on mitochondrial functions: protection against methamphetamine-induced mitochondrial damage. Int. J. Neuropsychopharmacol. 2009; 2: 805-822.
111. Mai L, Jope RS, Li X,. BDNF-mediated signal transduction is modulated by GSK3beta and mood stabilizing agents. J. Neurochem. 2002; 82: 75-83. (Pubitemid 34755251)
112. Ketter TA, Manji HK, Post RM,. Potential mechanisms of action of lamotrigine in the treatment of bipolar disorders. J. Clin. Psychopharmacol. 2003; 23: 484-495. (Pubitemid 37128677)
113. Hassel B, TaubÃll E, Gjestad L,. Chronic lamotrigine treatment increases rat hippocampal shunt activity and elevates cerebral taurine levels. Epilepsy Res. 2001; 43: 153-163. (Pubitemid 32115526)
114. Ahmad S, Fowler LJ, Whitton PS,. Effects of combined lamotrigine and valproate on basal and stimulated extracellular amino acids and monoamines in the hippocampus of freely moving rats. Naunyn Schmiedebergs Arch. Pharmacol. 2005; 371: 1-8. (Pubitemid 40379382)
115. Ahmad S, Fowler LJ, Whitton PS,. Effect of acute and chronic lamotrigine on basal and stimulated extracellular 5-hydroxytryptamine and dopamine in the hippocampus of the freely moving rat. Br. J. Pharmacol. 2004; 142: 136-142. (Pubitemid 38698202)
116. Kim YJ, Ko HH, Han ES, Lee CS,. Lamotrigine inhibition of rotenone- or 1-methyl-4-phenylpyridinium-induced mitochondrial damage and cell death. Brain Res. Bull. 2007; 71: 633-640. (Pubitemid 46209530)
117. Chen G, Pan B, Hawver DB, Wright CB, Potter WZ, Manji HK,. Attenuation of cyclic AMP production by carbamazepine. J. Neurochem. 1996; 67: 2079-2086. (Pubitemid 26349685)
118. Bown CD, Wang JF, Young LT,. Attenuation of N-methyl-D-aspartate-mediated cytoplasmic vacuolization in primary rat hippocampal neurons by mood stabilizers. Neuroscience 2003; 117: 949-955. (Pubitemid 36332312)
119. Berger I, Segal I, Shmueli D, Saada A,. The effect of antiepileptic drugs on mitochondrial activity: a pilot study. J. Child Neurol. 2010; 25: 541-545.
120. Prince JA, Yassin MS, Oreland L,. Neuroleptic-induced mitochondrial enzyme alterations in the rat brain. J. Pharmacol. Exp. Ther. 1997; 280: 261-267. (Pubitemid 27171411)
121. Maurer I, Möller HJ,. Inhibition of complex I by neuroleptics in normal human brain cortex parallels the extrapyramidal toxicity of neuroleptics. Mol. Cell. Biochem. 1997; 174: 255-259. (Pubitemid 27404200)
122. Modica-Napolitano JS, Lagace CJ, Brennan WA, Aprille JR,. Differential effects of typical and atypical neuroleptics on mitochondrial function in vitro. Arch. Pharm. Res. 2003; 26: 951-959.
123. Balijepalli S, Kenchappa RS, Boyd MR, Ravindranath V,. Protein thiol oxidation by haloperidol results in inhibition of mitochondrial complex I in brain regions: comparison with atypical antipsychotics. Neurochem. Int. 2001; 38: 425-435. (Pubitemid 32166900)
124. Burkhardt C, Kelly JP, Lim YH, Filley CM, Parker WD Jr,. Neuroleptic medications inhibit complex I of the electron transport chain. Ann. Neurol. 1993; 33: 512-517. (Pubitemid 23143036)
125. Barrientos A, Moraes CT,. Simultaneous transfer of mitochondrial DNA and single chromosomes in somatic cells: a novel approach for the study of defects in nuclear-mitochondrial communication. Hum. Mol. Genet. 1998; 7: 1801-1808. (Pubitemid 28464156)
126. Matsubara T, Hagihara B,. Action mechanism of phenothiazine derivatives on mitochondrial respiration. J. Biochem. 1968; 63: 156-164.